Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Atezolizumab for PD-L1-Selected Patients with NSCLC.
Horita N, Fukuda N, Kaneko T. Horita N, et al. Among authors: fukuda n. N Engl J Med. 2021 Feb 11;384(6):583-584. doi: 10.1056/NEJMc2032432. N Engl J Med. 2021. PMID: 33567200 No abstract available.
T-cell response to phytohemagglutinin in the interferon-γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer.
Kamimaki C, Kobayashi N, Hirata M, Somekawa K, Fukuda N, Kubo S, Katakura S, Teranishi S, Watanabe K, Horita N, Hara Y, Yamamoto M, Kudo M, Piao H, Kaneko T. Kamimaki C, et al. Among authors: fukuda n. Thorac Cancer. 2021 Jun;12(11):1726-1734. doi: 10.1111/1759-7714.13978. Epub 2021 May 4. Thorac Cancer. 2021. PMID: 33943031 Free PMC article.
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial.
Matsumoto H, Kobayashi N, Somekawa K, Fukuda N, Kaneko A, Kamimaki C, Kubo S, Tanaka K, Tagami Y, Teranishi S, Watanabe K, Horita N, Hara Y, Yamamoto M, Kudo M, Koizumi H, Miura K, Miyazawa N, Kaneko T. Matsumoto H, et al. Among authors: fukuda n. Thorac Cancer. 2022 Jan;13(2):228-235. doi: 10.1111/1759-7714.14252. Epub 2021 Dec 5. Thorac Cancer. 2022. PMID: 34866339 Free PMC article.
Adverse events induced by nivolumab and ipilimumab combination regimens.
Somekawa K, Horita N, Kaneko A, Tagami Y, Fukuda N, Matsumoto H, Namkoong H, Fujiwara Y, Minegishi K, Fukumoto T, Watanabe K, Hara Y, Kobayashi N, Kaneko T. Somekawa K, et al. Among authors: fukuda n. Ther Adv Med Oncol. 2022 Feb 11;14:17588359211058393. doi: 10.1177/17588359211058393. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35173819 Free PMC article.
Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study.
Zhang D, Shi Y, Liu X, Liu J, Xu Y, Zhao J, Zhong W, Käsmann L, Hakozaki T, Provencio M, Horita N, Fukuda N, Chen M, Wang M. Zhang D, et al. Among authors: fukuda n. Transl Lung Cancer Res. 2022 Jul;11(7):1420-1433. doi: 10.21037/tlcr-22-464. Transl Lung Cancer Res. 2022. PMID: 35958331 Free PMC article.
1,254 results